کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5569801 | 1403728 | 2017 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Use of Incretin Therapy in the Treatment of Type 2 Diabetes Mellitus
ترجمه فارسی عنوان
استفاده از درمان داروی تزریقی در درمان دیابت نوع 2
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی و دندانپزشکی (عمومی)
چکیده انگلیسی
Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are 2 of 6 second-line medication options in diabetes management according to the 2016 American Diabetes Association guidelines. Providers must take many factors into consideration when choosing a treatment regimen, including patient preference, cost and insurance coverage, efficacy, and tolerability. Side effects, such as hypoglycemia and weight gain, often contribute to lack of control and poor adherence. Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are well-tolerated options that improve glycemic control with a low incidence of hypoglycemia and weight gain. In this article we review the similarities, differences, advantages, and disadvantages of the incretin therapies.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal for Nurse Practitioners - Volume 13, Issue 6, June 2017, Pages 418-424
Journal: The Journal for Nurse Practitioners - Volume 13, Issue 6, June 2017, Pages 418-424
نویسندگان
Michelle P. DNP, FNP-BC, Meredith FNP-BC, CDE, Benita PhD, FNP-BC,